Astrazeneca Ab

Astra Pharmaceuticals Limited

Garry Pairaudeau

Stephen Thom

Anil Patel

Roger Victor Bonnert

Brian Springthorpe

Andrew Bailey

Roger Brown

Thomas McInally

Timothy Jon Luker

Nicholas David Kindon

Paul Andrew Willis

Roger C Brown

Francis Ince

Simon David Guile

Stephen Brough

Lilian Alcaraz

Andrew Baxter

Bryan Glyn Roberts

Michael Stocks

Rukhsana Rasul

Ian Millichip

Peter A Cage

Alice Flaherty

Andrew Lister

Judith McInally

Andrew Davies

Andrew Davis

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. 

Compounds

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta adrenoreceptor agonists. 

Bezothiazol derivatives as Beta2 adrenoreceptor agonists

The present invention provides compounds of formula (I) wherein e, R, R, R, R, R, R, R, R, R, R, R, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. 

Benzothiazolone derivatives

The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.

Cathepsin cysteine protease inhibitors and their use

The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors. 

Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity

The present invention therefore provides use of a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition, this invention also discloses processes for the preparation of such inhibitors 

Use of pyrimidine&#x2014;or triazine&#x2014;2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives

The invention provides novel 1,2,3-triazolo[4,5-d]pyrimidine compounds, such as those represented by formula (I):their use as medicaments, particularly in platelet aggregation disorders, compositions containing them and processes for their preparation.

Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine compounds

The invention provides piperidine compounds of general formula (I) in which A, B, X, Y, Z, R, R and R are as defined in the specification, their use as medicaments, compositions containing them and processes for their for their preparation.

P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular disease

Triazolo(4,5-d)pyrimidine compounds

Growing community of inventors

Loughborough, United Kingdom

Garry Pairaudeau